ResearcherUniversità Cattolica del Sacro CuoreActive in the last 2 years
Alessia Caggiano
Matched on OpenAlex author ID A5016217004. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 5
- Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibition in Pancreatic Cancer Co-author DOI 10.34133/cancomm.0030↗
- Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic… Co-author DOI 10.1186/s13046-024-03238-x↗
- CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. Co-author DOI 10.1038/s41416-022-02028-6↗
- Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer. Co-author DOI 10.1186/s12967-023-04733-z↗
- Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and a promising therapeutic target Co-author DOI 10.21203/rs.3.rs-2095432/v1↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Vincenzo Corbo · 5 shared papers, 2022–2026 · strength 0.86
- Paper Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibiti… DOI 10.34133/cancomm.0030↗
- Paper Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pa… DOI 10.1186/s13046-024-03238-x↗
- Paper CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. DOI 10.1038/s41416-022-02028-6↗
- Antonio Agostini · 5 shared papers, 2022–2026 · strength 0.86
- Paper Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibiti… DOI 10.34133/cancomm.0030↗
- Paper Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pa… DOI 10.1186/s13046-024-03238-x↗
- Paper CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. DOI 10.1038/s41416-022-02028-6↗
- Geny Piro · 5 shared papers, 2022–2026 · strength 0.86
- Paper Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibiti… DOI 10.34133/cancomm.0030↗
- Paper Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pa… DOI 10.1186/s13046-024-03238-x↗
- Paper CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. DOI 10.1038/s41416-022-02028-6↗
- Giampaolo Tortora · 5 shared papers, 2022–2026 · strength 0.86
- Paper Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibiti… DOI 10.34133/cancomm.0030↗
- Paper Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pa… DOI 10.1186/s13046-024-03238-x↗
- Paper CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. DOI 10.1038/s41416-022-02028-6↗
- Carmine Carbone · 5 shared papers, 2022–2026 · strength 0.86
- Paper Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibiti… DOI 10.34133/cancomm.0030↗
- Paper Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pa… DOI 10.1186/s13046-024-03238-x↗
- Paper CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. DOI 10.1038/s41416-022-02028-6↗
- Francesco De Sanctis · 4 shared papers, 2023–2026 · strength 0.72
- Paper Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibiti… DOI 10.34133/cancomm.0030↗
- Paper Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pa… DOI 10.1186/s13046-024-03238-x↗
- Paper CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. DOI 10.1038/s41416-022-02028-6↗
- Alberto Larghi · 2 shared papers, 2022–2023 · strength 0.27
- Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
- Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
- Giuseppe Quero · 2 shared papers, 2022–2023 · strength 0.27
- Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
- Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
- Sergio Alfieri · 2 shared papers, 2022–2023 · strength 0.27
- Paper Spatial transcriptomics identified mucin-specific O-glycosylation as a key pathway in pancreatic cancer development and… DOI 10.21203/rs.3.rs-2095432/v1↗
- Paper Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment … DOI 10.1186/s12967-023-04733-z↗
- Vincenzo Bronte · 1 shared paper, 2026 · strength 0.23
- Claudio Sette · 1 shared paper, 2026 · strength 0.23
- Gian Luca Rampioni Vinciguerra · 1 shared paper, 2026 · strength 0.23
- Lisa Salvatore · 1 shared paper, 2025 · strength 0.21
- Rita Teresa Lawlor · 1 shared paper, 2023 · strength 0.15
- Aldo Scarpa · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.